PM
ALNY icon

Prosight Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Prosight Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.1M Buy
76,000
+58,891
+344% +$20M 4.12% 10
2025
Q4 		$6.8M Buy
+17,109
New +$7.57M 1.41% 23
2022
Q2 		– Sell
-22,704
Closed -$3.71M – 26
2022
Q1 		$3.71M Sell
22,704
-9,203
-29% -$1.4M 2.39% 12
2021
Q4 		$5.41M Buy
+31,907
New +$5.93M 3.24% 13

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prosight Management's ALNY Position: Q1 2026 in Review

Prosight Management increased its Alnylam Pharmaceuticals (ALNY) stake by 344% in Q1 2026, buying an estimated $20M and bringing the position to 76,000 shares worth $25.1M. The position accounts for 4.12% of the portfolio, ranked #10.

Prosight Management first reported a position in ALNY in Q4 2021 and has held it in 4 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Prosight Management held 76,000 shares of Alnylam Pharmaceuticals worth $25.1M as of Q1 2026.
  • Prosight Management bought 58,891 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $20M.
  • Alnylam Pharmaceuticals made up 4.12% of Prosight Management's portfolio in Q1 2026, its #10 holding.
  • Prosight Management first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.